APSR2026-724

Yes
Late-Breaking
Submitted
Poster Presentation
 
AP10-022
P22
 
Format: PPTX Only
https://storage.unitedwebnetwork.com/files/1285/1221175-46904-APSR26_Poster_AP10-022_439752.pdf
Format: PDF Only
07. COPD
5

No more than 15 authors can be listed.
Please ensure the authors are listed in the right order.
If there are multiple affiliations, please use the "+" button next to "Select Country/Region" to add additional affiliation fields.

Hyonsoo Joo * The Catholic University of Korea Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine Seoul Korea, ROK (South)
Youlim Kim - Konkuk University Medical Center Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Internal Medicine Seoul Korea, ROK (South)
Chinkook Rhee - The Catholic University of Korea Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine Seoul Korea, ROK (South)
Kwang Ha Yoo - Konkuk University Medical Center Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Internal Medicine Seoul Korea, ROK (South)
Ji-Yong Moon - Konkuk University Medical Center Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Internal Medicine Seoul Korea, ROK (South)
 
 
 
 
 
 
 
 
 
 
Presenting Author Details
Hyonsoo
Joo
arztzu@gmail.com
+821020003184
41-50
 
Original Research
Small Airway Dysfunction Assessed by FEF25-75 and the risk of COPD Exacerbations: Analysis from the Prospective KOCOSS Cohort
Maximum 25 words
Abstract Content
Small airway dysfunction is a characteristic feature of chronic obstructive pulmonary disease (COPD), yet the prognostic value of spirometry-derived markers for small airway disease remains insufficiently explored in large prospective cohorts. We investigated the association between forced expiratory flow between 25% and 75% of forced vital capacity (FEF25-75) and the risk of COPD exacerbations.
Data were analyzed from the Korean COPD Subgroup Study (KOCOSS), a nationwide multicenter prospective cohort. Small airway dysfunction was assessed using baseline pre-bronchodilator FEF25-75 (% predicted). Participants were stratified into quartiles (Q1: 5–15%, Q2: 16–23%, Q3: 24–35%, Q4: 36–131%). The primary outcome was the occurrence of moderate-to-severe exacerbations over a one-year follow-up. The discriminatory performance of FEF25-75 was compared with the residual volume to total lung capacity ratio (RV/TLC) using Area Under the Curve (AUC) analysis.
A total of 1,239 patients were included in the final analysis. Lower FEF25-75 was associated with a stepwise increase in exacerbation risk (moderate-to-severe exacerbation rates: 57.4% in Q1 vs. 28.9% in Q4; p < 0.001). In multivariable logistic regression adjusted for symptom burden (CAT or mMRC), age, BMI, and smoking history, each 10-percentage-point decrease in FEF25-75 was associated with a higher risk of moderate (aOR 1.18, 95% CI 1.08–1.30) and severe exacerbations (aOR 1.30, 95% CI 1.10–1.55). Notably, FEF25-75 demonstrated comparable discriminatory power to RV/TLC for predicting one-year moderate-to-severe exacerbations (AUC 0.606 vs. 0.637, DeLong p = 0.129) and severe exacerbations (AUC 0.671 vs. 0.661, p = 0.768).
Baseline FEF25-75 is an independent and readily accessible predictor of COPD exacerbations. Its prognostic performance is non-inferior to RV/TLC, suggesting that FEF25-75 can serve as a practical surrogate for small airway dysfunction to identify patients at high risk of clinical instability in settings where lung volume measurements are unavailable.
 
 
 
 
 
No
No
 
JPG or JPEG or PNG format ONLY
FEF25-75,small airway dysfunction, COPD
maximum 3 keywords and no abbreviations, separated by commas
None
308